References
- Hu B, Huang S, Yin L. The cytokine storm and COVID-19. J Med Virol. 2020 [2020 June 28]. doi:10.1002/jmv.26232.
- Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm‘ in COVID-19. J Infect. 2020 [2020 April 14];80(6):607–13. doi:10.1016/j.jinf.2020.03.037.
- Meftahi G, Jangravi Z, Sahraei H, Bahari Z. The possible pathophysiology mechanism of cytokine storm in elderly adults with COVID-19 infection: the contribution of “inflame-aging”. Inflamm Res. 2020 [2020 June 13]:1–15. doi:10.1007/s00011-020-01372-8.
- Lakatos B, Gopcsa L, Gondos E, Riczu A, Várnai Z, Nagy É, Molnár E, Bekő G, Bobek I, Reményi P, et al. [Anti-cytokine therapy in novel coronavirus disease (COVID-19) – the first administration of TTocilizumab in Hungary at a department of infectology]. Orv Hetil. 2020 [2020 June 17];161:1070–77. doi:10.1556/650.2020.31899.
- Luo P, Liu Y, Qiu L, Liu X, Liu D, Li J. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020 [2020 April 8];92(7):814–18. doi:10.1002/jmv.25801.
- Alzghari SK, Acuña VS. Supportive treatment with tocilizumab for COVID-19: a systematic review. J Clin Virol. 2020 [2020 May 1];127:104380. doi:10.1016/j.jcv.2020.104380.
- Toniati P, Piva S, Cattalini M, Garrafa E, Regola F, Castelli F, Franceschini F, Airò P, Bazzani C, Beindorf E-A, et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun Rev. 2020;19(7):102568. doi:10.1016/j.autrev.2020.102568.